The UK Court of Appeal ruled that Actavis’s alternative salt forms of pemetrexed would indirectly infringe Eli Lilly’s cancer drug patent. The decision provides insights into patent claim construction and the approach to pharmaceutical patent disputes across multiple European jurisdictions.
Read more about Patent Infringement Claim on Cancer Treatment Drug